3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
3
Head & Neck
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Endometrial Neoplasms
19
Ovarian Neoplasms
8
Uterine Cervical Neoplasms
7
Triple Negative Breast Neoplasms
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Neoplasms
4
Stomach Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Colorectal Neoplasms
3
Carcinoma, Transitional Cell
3
Carcinoma, Renal Cell
3
Carcinoma, Ovarian Epithelial
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Hepatocellular
3
Vulvar Neoplasms
2
Thyroid Neoplasms
2
Neoplasm Metastasis
2
Fallopian Tube Neoplasms
2
Advanced Endometrial Cancer
2
Adenocarcinoma
2
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Small Cell Lung Carcinoma
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Diseases
1
Ovarian Clear Cell Carcinoma
1
Neoplasms, Glandular and Epithelial
1
Melanoma
1
Liver Neoplasms
1
Interventions
pembrolizumab
24
Paclitaxel
7
Docetaxel
7
Cyclophosphamide
7
Carboplatin
7
fludarabine
6
Taxes
6
Nivolumab
6
Trastuzumab
5
Magnetic Resonance Spectroscopy
5
atezolizumab
4
Specimen Handling
4
Psychiatric Rehabilitation
4
Polymerase Chain Reaction
4
Gemcitabine
4
Fluorouracil
4
Cisplatin
4
tisotumab vedotin
3
fludarabine phosphate
3
Radiation
3
Oxaliplatin
3
Leucovorin
3
Irinotecan
3
Ipilimumab
3
Gene Expression Profiling
3
Drug Therapy
3
Counseling
3
Albumin-Bound Paclitaxel
3
zimberelimab
2
ulixertinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
lenvatinib
×
Gynecologic
×
Clear all
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled